Revenue is not the scoreboard: earnings season rewards what each dollar is worth

The five-percent quarter that beat the 45-percent quarters

The most instructive number this season is not a growth rate. ADMA Biologics reported total revenue of $141.1 million, up just 5% year over year. On that line alone it trails Arcutis and Innoviva's specialty business, which both grew 45%. Yet ADMA's GAAP net income rose 37% to $49.9 million. Adjusted EBITDA rose 32% to $77.3 million, and gross margin of 71% expanded by roughly 1,450 basis points. The engine was ASCENIV, up 31% to $124.7 million, so the mix of revenue improved even as the total barely moved.

That is the argument of this column. In a season crowded with raised guidance and double-digit growth, the useful question is what each incremental dollar is worth and how much of it survives to cash and GAAP earnings. Headline growth is the easiest figure to produce and the least informative one to read in isolation.

Quality shows up in the gaps

Look at how far reported results sit from adjusted ones. ADMA's GAAP net income of $49.9 million and adjusted net income of $51.1 million are close. Organogenesis, in sharp contrast, reported a net loss of $29.6 million against an adjusted net loss of $29.3 million, so no adjustment rescues the picture. Its net revenue fell $105.0 million to $45.5 million, and its Advanced Wound Care sales dropped 73%. Keenova reported net sales from continuing operations of $550 million and adjusted EBITDA of $233 million, alongside a $96 million loss from continuing operations. The two measures are different by design, and the material we reviewed does not itemise the bridge. That is exactly the point: when an executive team asks the market to look at the adjusted figure, the bridge deserves as much airtime as the headline.

Cash is the other honest witness. Arcutis grew ZORYVE net product revenue to $143.9 million, up 45% year on year and 11% on the prior quarter, and still generated $18.9 million of net cash from operations. Zymeworks raised 2026 guidance to $337 million to $351 million in revenue, and the approval milestone of $250 million shows how lumpy that kind of income can be. Both are real results, but they are different kinds of revenue, and a board should not weigh them the same.

The strongest counter-argument

The fair objection is that this favours the mature over the ambitious. A launch-stage company should be judged on demand and trajectory, not on margin. Arcutis's sequential growth and Innoviva's specialty sales of $43.3 million, up 45% and on track for its guidance of at least $150 million, are exactly what a healthy launch looks like. Adjusted measures also strip out genuine one-offs, and Keenova's integration is the sort of event where that matters. Penalising growth for not yet looking like ADMA's income statement would be a mistake.

I accept all of that, and it does not change the conclusion. It sharpens it. Growth deserves credit when it is demand-driven and visibly heading toward cash, as Arcutis's operating cash flow suggests. It deserves scepticism when the reader cannot tell how much of it will repeat, or what sits between the adjusted number and the GAAP one.

What this means for the industry

Revenue is a necessary figure, not a sufficient one. Companies that can show mix improving, margin expanding, cash arriving and adjustments that are small or well explained are building the kind of results that hold up when conditions change. Those that lean on a single growth rate, or on income that arrives in one lump, are asking readers to take more on trust than the numbers justify.

— The Editor, CompePharma